Back to Search

PHILLIP MATAR, MD

MD

Pediatrics Physician

NPI: 1528367729Individual

Specialties, Licenses & Credentials

Student in an Organized Health Care Education/Training Program

Student in an Organized Health Care Education/Training Program

Code: 390200000X

Pediatrics PhysicianPrimary

Pediatrics

Code: 208000000X

ME 119833(FL)

Research & Publications (15)

Immunotherapy for liver tumors: present status and future prospects.
PMID 19272130·J Biomed Sci·2009
6-review
Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response.
PMID 19185418·Cancer Lett·2009
7-preclinical
Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models.
PMID 18425377·Oncol Rep·2008
7-preclinical
Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment.
PMID 17571260·Cancer Immunol Immunother·2007
6-review
The transition to the metastatic phenotype of rat lymphoma cells involves up-regulation of IL-10 receptor expression and IL-10 secretion.
PMID 16086233·Clin Exp Metastasis·2005
7-preclinical
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
PMID 15475436·Clin Cancer Res·2004
7-preclinical
Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity.
PMID 15367416·Ann Oncol·2004
7-preclinical
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)].
PMID 15289751·Minerva Med·2004
6-review
Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin.
PMID 12820652·Cell Stress Chaperones·2003
7-preclinical
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
PMID 12684395·Clin Cancer Res·2003
8-other
Differential production of angiostatin by concomitant antitumoral resistance-inducing cancer cells.
PMID 12115581·Int J Cancer·2002
7-preclinical
The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression.
PMID 11807623·Cancer Immunol Immunother·2002
7-preclinical
Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model.
PMID 11807622·Cancer Immunol Immunother·2002
7-preclinical
Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response.
PMID 11360931·Int Immunopharmacol·2001
7-preclinical
Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide.
PMID 10885612·Eur J Cancer·2000
7-preclinical

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
501 6TH ST S
ST PETERSBURG, FL 33701

Location

Practice Location

501 6TH ST S, ST PETERSBURG, FL
(954) 662-3059

Quick Facts

NPI
1528367729
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
2
Locations
1
Publications
15

Are you this provider?

Claim Your Profile